Anti-myeloma activity of natural killer lymphocytes. 2002

Christoph Frohn, and Maike Höppner, and Peter Schlenke, and Holger Kirchner, and Petra Koritke, and Jürgen Luhm
Institute of Immunology and Transfusion Medicine, University of Lübeck, Lübeck, Germany.

Natural killer (NK) cells are assumed to contribute to a graft-versus-leukaemia effect. In vitro experiments have shown that many leukaemic cells are NK-cell sensitive. Nevertheless, no data concerning the influence of purified NK cells on malignant myeloma (MM) cells exist. We co-incubated NK cells with three different MM cell lines and fresh bone marrow samples of nine MM patients. The proportion of vital MM cells was determined before and after co-cultivation by a flow-cytometry-based assay. All MM cells tested, with the exception of one cell line (NCI H929), were susceptible to a NK-cell attack even without exogenous interleukin 2 (IL-2). The mean killing of the native MM samples was 23.1 +/- 5.4% and 34.5 +/- 6.5% at 10:1 and 20:1 effector:target ratio respectively, This corresponded to about 2/3 of those values obtained with the highly sensitive line K562. In contrast, CD34-positive haematopoietic stem cells as well as peripheral mononuclear cells were completely resistant under similar experimental conditions (1.3% killing). To elucidate the underlying triggering mechanisms, we measured human leucocyte antigen (HLA)-class I expression of the MM cells. No evidence for HLA loss, which could have explained the NK-cell recognition if it occurred, was demonstrated. These findings may contribute to the understanding of in vivo NK-cell activation and encourage clinical applications of NK cells for MM patients.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D005805 Genes, MHC Class I Genetic loci in the vertebrate major histocompatibility complex which encode polymorphic characteristics not related to immune responsiveness or complement activity, e.g., B loci (chicken), DLA (dog), GPLA (guinea pig), H-2 (mouse), RT-1 (rat), HLA-A, -B, and -C class I genes of man. Class I Genes,Genes, Class I,Genes, H-2 Class I,Genes, HLA Class I,MHC Class I Genes,H-2 Class I Genes,HLA Class I Genes,Class I Gene,Gene, Class I,Genes, H 2 Class I,H 2 Class I Genes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D020544 Graft vs Leukemia Effect Immunological rejection of leukemia cells following bone marrow transplantation. Graft vs Leukemia Response,Graft-vs-Leukemia Effect,Graft-vs-Leukemia Response,Effect, Graft-vs-Leukemia,Effects, Graft-vs-Leukemia,Graft-vs-Leukemia Effects,Graft-vs-Leukemia Responses,Response, Graft-vs-Leukemia,Responses, Graft-vs-Leukemia

Related Publications

Christoph Frohn, and Maike Höppner, and Peter Schlenke, and Holger Kirchner, and Petra Koritke, and Jürgen Luhm
November 2018, Cancer treatment reviews,
Christoph Frohn, and Maike Höppner, and Peter Schlenke, and Holger Kirchner, and Petra Koritke, and Jürgen Luhm
July 1996, Immunobiology,
Christoph Frohn, and Maike Höppner, and Peter Schlenke, and Holger Kirchner, and Petra Koritke, and Jürgen Luhm
October 1982, Molecular immunology,
Christoph Frohn, and Maike Höppner, and Peter Schlenke, and Holger Kirchner, and Petra Koritke, and Jürgen Luhm
January 1979, Annales immunologiae Hungaricae,
Christoph Frohn, and Maike Höppner, and Peter Schlenke, and Holger Kirchner, and Petra Koritke, and Jürgen Luhm
July 2023, Cell death & disease,
Christoph Frohn, and Maike Höppner, and Peter Schlenke, and Holger Kirchner, and Petra Koritke, and Jürgen Luhm
December 2007, Experimental hematology,
Christoph Frohn, and Maike Höppner, and Peter Schlenke, and Holger Kirchner, and Petra Koritke, and Jürgen Luhm
March 2019, Sensors and actuators. B, Chemical,
Christoph Frohn, and Maike Höppner, and Peter Schlenke, and Holger Kirchner, and Petra Koritke, and Jürgen Luhm
January 1987, Progress in clinical and biological research,
Christoph Frohn, and Maike Höppner, and Peter Schlenke, and Holger Kirchner, and Petra Koritke, and Jürgen Luhm
January 1988, Cancer detection and prevention,
Christoph Frohn, and Maike Höppner, and Peter Schlenke, and Holger Kirchner, and Petra Koritke, and Jürgen Luhm
January 1983, Natural immunity and cell growth regulation,
Copied contents to your clipboard!